Evotec AG announced today that it has earned a $ 2 m milestone payment from Second Genome, Inc., a leading microbiome science-based discovery & development company, for the initiation of a Phase II clinical study of SGM 1019, a first-in-class oral therapeutic for the treatment of nonalcoholic steatohepatitis (NASH). The Phase II trial of SGM-1019 has been initiated following the completion of two successful Phase I trials. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-milestone-payment-for-start-of-phase-ii-clinical-trial-5773